DG DISPATCH - EULAR: Leflunomide Of Benefit In Active RA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - EULAR: Leflunomide Of Benefit In Active RA

By David Jack
Special to DG News

GLASGOW, SCOTLAND -- June 9, 1999 -- Hoechst Marion Roussel’s leflunomide is more effective than methotrextate in improving health status measures and functional activities in patients with rheumatoid arthritis, according to the results of a study presented by Dr. P. Tugwell, from the University of Ottawa, and colleagues from the Leflunomide US Investigators Group.

The results of their study were presented at a poster session yesterday during the European League Against Rheumatism (EULAR).

Leflunomide is one of the new disease-modifying antirheumatic drugs. The 12-month, multi-centre, randomised, placebo-controlled trial compared the efficacy of leflunomide with methotrexate.

A total of 482 patients were randomised to receive either leflunomide 20 mg daily after a 100 mg loading dose for three days, methotrexate 7.5 to 15.0 mg/weekly or placebo. A Modified Health Assessment Questionnaire was administered monthly, Problem Elicitation Technique and Medical Outcomes Survey Short Form 36 at baseline, 24 and 52 weeks.

Mean changes in test scores showed a significant improvement in function and health related quality of life with leflunomide treatment compared with placebo. Many of the other parameters were also significantly improved.

Leflunomide produced significantly greater improvements than methotrexate in the Modified Health Assessment Questionnaire, five of the eight Health Assessment Questionnaire Scales and Disability Index, weighted top five of Problem Elicitation Technique and two of eight subscores of the Medical Outcomes Survey Short Form 36.

The researchers concluded that functional ability improved from baseline in both active treatment groups but that leflunomide produced a significantly greater improvement than methotrexate in health status measures and functional activities which are considered important for a patient’s health-related quality of life.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities